Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Investor Presentation (November 2025)
9 slides from Bioporto A/s's investor presentation, Nov 19, 2025
Slide 1: Transforming Care Through Actionable Kidney Biomarkers
BioPorto Transforming Care Through Actionable Kidney Biomarkers Investor Presentation November 19, 2025 CONFIDENTIAL | © Copyright BioPorto | 1
Slide 2: Forward-looking statements
Forward-looking statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: Invest in AKI Diagnostic - Invest in BioPorto
Invest in AKI Diagnostic - Invest in BioPorto Early detection of AKI (Acute Kidney Injury) represents a major unmet need1 BioPorto’s ProNephro AKI (NGAL) is the first FDA-cleared test for pediatric AKI assessment Defined pathway for FDA approval and commercial launch of ProNephro AKI (NGAL) for adul
Slide 4: The "Forward" Strategic Plan
The ”Forward” Strategic Plan Focus on Execution of Market Access & Commercialization to transform kidney care Aspirations 1 Adoption +60 US Hospitals 2H 2027 Cash + Validation Study flow Positive 2026 High +100 Global Hospitals FY 2028 Revenue 2 Growth + Adult Indication 2027 150-200m DKK +170 Globa
Slide 5: Highlights for the third quarter of 2025
Highlights for the third quarter of 2025 ✓ A major milestone in the third quarter of 2025 was the delivery of the first TOTAL REVENUE (Q3 2025) purchase order for ProNephroTM AKI (NGAL) for the US market, marking the first step in the commercial launch DKK 10.4 million 7% increase compared to Q3 202
Slide 6: Continued NGAL growth in Q3 2025 vs Q3 2024
Continued NGAL growth in Q3 2025 vs Q3 2024 Revenue Q3 2025 vs Q3 2024, DKKm Revenue per quarter, DKKm 9M 2025 vs 9M 2024 US NGAL RUO +20% (+27%) ROW NGAL -87% Total revenue +7% (+10%) ProNephro AKI (NGAL) +2.1m DKK 28.7m +1% (+2%) 10.6 10.4 10.4 9.7 +5% 9.5 9.7 9.2 (+10%) 8.6 8.0 7.7 7.7 7.8 7.2 6.
Slide 7: NGAL Sales US continuing strong growth projection
NGAL Sales US continuing strong growth projection US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates) 18 +24% 17 16.1 16 15.1 15 14.2 14 13.7 13.0 13 12.3 11.8 DKKm 12 11 10.1 10.2 10 8.7 9 7.9 8 7 6 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2
Slide 8: Closing of funding round in November 2025
Closing of funding round in November 2025 raising app. DKK 43m FUNDING TOWARDS CASH FLOW POSITIVE PARTLY RAISED • Funding needs communicated on November 4, was DKK 60-70m to cash flow positive in second half of 2027 • On November 13, BioPorto successfully completed a direct issue of app. 40 million
Slide 9: Q&A
Q&A